Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Inventory: 2023-2025

Historic Inventory for Iovance Biotherapeutics (IOVA) over the last 2 years, with Sep 2025 value amounting to $51.7 million.

  • Iovance Biotherapeutics' Inventory was N/A to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year change of. This contributed to the annual value of $51.5 million for FY2024, which is 396.72% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Inventory is $51.7 million, which was up 3.77% from $49.8 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Inventory ranged from a high of $65.5 million in Q1 2025 and a low of $9.2 million during Q3 2023.
  • Its 3-year average for Inventory is $33.2 million, with a median of $33.7 million in 2024.
  • Data for Iovance Biotherapeutics' Inventory shows a peak YoY soared of 396.72% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Inventory (Quarterly) stood at $10.4 million in 2023, then spiked by 396.72% to $51.5 million in 2024, then spiked by 272.06% to $51.7 million in 2025.
  • Its last three reported values are $51.7 million in Q3 2025, $49.8 million for Q2 2025, and $65.5 million during Q1 2025.